# Xeloda Plus Paclitaxel in Gastric Cancer With Liver Metastasis

> **NCT01167049** · PHASE2 · UNKNOWN · sponsor: **Peking University Cancer Hospital & Institute** · enrollment: 60 (estimated)

## Conditions studied

- Gastric Cancer

## Interventions

- **DRUG:** CAPECITABINE

## Key facts

- **NCT ID:** NCT01167049
- **Lead sponsor:** Peking University Cancer Hospital & Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2009-08
- **Primary completion:** 2013-12
- **Final completion:** 2013-12
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2010-07-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01167049

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01167049, "Xeloda Plus Paclitaxel in Gastric Cancer With Liver Metastasis". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT01167049. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*